News

The latest from Cogstate, leaders in optimizing the measurement of cognition

New Study Of HIV−Associated Neurocognitive Disorders (HAND) Uses An Innovative Approach To Functional Assessments For Activities Of Daily Living And Correlates To Cogstate Test Performance 

November 23, 2017

Navigating the Internet to get daily shopping and banking tasks done has become a necessary skill for just about all of us. Searching for products, comparing pricing, entering credit card and shipping information across multiple websites can sometimes be challenging even for experienced users. But for those persons who also struggle with cognitive dysfunction from […]

New Study Shows Prolonged Site Exposure Among World Trade Center First Responders Is Associated with Cognitive Dysfunction

November 17, 2017

More than sixteen years after the horrific terrorist attacks at the World Trade Center (WTC) in New York City on September 11, 2001, there is still a large segment of the first responders that suffers from cognitive dysfunction as a result of their rescue and recovery efforts. Two leading explanations include the exposure to contaminated […]

Cogstate Announces First U.S. Deployment of the Cognigram™ System at the University of Notre Dame

October 11, 2017

BOSTON – October 11, 2017: The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in […]

Study Evaluates Computer-Based Cognitive Tests to Detect Impairment in Cirrhosis Patients with Hepatic Encephalopathy (HE)

October 11, 2017

Hepatic encephalopathy (HE) is one of the most challenging consequences of cirrhosis, a type of chronic liver disease, as it causes significant cognitive dysfunction in patients. Diagnosing HE has traditionally been done through a psychometric testing battery involving paper and pencil tests designed to assess motor speed, visual perception, visual-spatial orientation, concentration, attention and memory. […]

Cogstate receives positive FDA notification regarding medical device regulatory submission

July 27, 2017

Company to launch COGNIGRAMTM digital cognitive testing tool in U.S. healthcare market Boston, MA – July 27, 2017: The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k) submission (K171658) for the COGNIGRAMTM cognitive assessment system has been reviewed […]

Pilot Study Demonstrates Working Memory Training May Be Effective For Children With Neurofibromatosis

June 27, 2017

While neurofibromatosis often appears in children as visible spots, freckles or tiny bumps, the genetic disorder can also cause learning disabilities, including problems with attention, working memory, inhibition and planning. Up to 40% of children with neurofibromatosis type 1 (NF1) are diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD). These symptoms can often cause issues at home […]

Cogstate Selected as Preferred Provider to Lilly’s Alzheimer’s Disease Platform

May 17, 2017

Company to Deliver Novel Solutions to Ensure High-quality Neuropsychological Measures in Clinical Trials New Haven, CT – May 17, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen as the preferred provider to the global healthcare leader, Eli Lilly and Company, to support their Alzheimer’s disease platform with solutions to ensure […]

Cogstate Brief Battery Effective For Detecting Cognitive Impairment in Pediatric MS Patients

May 12, 2017

While multiple sclerosis (MS) is most often diagnosed in adults, symptoms can begin much earlier in life. Pediatric onset MS (POMS) affects 8,000-10,000 children under the age of 18 in the U.S., while an additional estimated 10,000 have at least one symptom. Diagnosis can be difficult as physicians often default to more common childhood disorders […]

Cogstate Brief Battery Shows Correlation With Traditional Tests of Cognition In Breast Cancer Population

May 1, 2017

As the complexity and geographic distribution of clinical trials increase, there is a growing need for more efficient cognitive testing of participants. Traditional “pencil and paper” neuropsychological tests have been the gold standard but require expert administration and manual data collection. To scale to hundreds of patients located around the world, computerized cognitive testing offers […]

Cogstate Strengthens Executive Team with Appointment of Chief Technology Officer

March 15, 2017

New Haven, CT – March 15, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) announced today that Richard Gleeson has joined the senior leadership team as Chief Technology Officer, strengthening the company’s ability to deliver transformative innovations to optimize the measurement of cognition in clinical trials and healthcare. Reporting directly to Cogstate Chief Operating Officer, […]

1 2 3